1. The cytokine network in acute myeloid leukemia (AML): A focus on pro- and anti-inflammatory mediators
- Author
-
Stephanie Binder, Jutta Horejs-Hoeck, and Michela Luciano
- Subjects
0301 basic medicine ,medicine.drug_class ,Endocrinology, Diabetes and Metabolism ,T-Lymphocytes ,Immunology ,Inflammation ,Context (language use) ,General Biochemistry, Genetics and Molecular Biology ,Anti-inflammatory ,03 medical and health sciences ,hemic and lymphatic diseases ,medicine ,Immunology and Allergy ,Animals ,Humans ,Interleukin 6 ,neoplasms ,biology ,business.industry ,Cell growth ,Myeloid leukemia ,Interleukin 10 ,Haematopoiesis ,Leukemia, Myeloid, Acute ,030104 developmental biology ,biology.protein ,Cancer research ,Cytokines ,medicine.symptom ,Inflammation Mediators ,business - Abstract
Cytokines exert profound effects on the progression of hematopoietic malignancies such as acute myeloid leukemia (AML). Critical roles of cytokines in the context of inflammation have gained special interest. While pro-inflammatory mediators such as IL-1β, TNF-α and IL-6 tend to increase AML aggressiveness, anti-inflammatory mediators such as TGF-β and IL-10 appear to impede AML progression. Dysregulation of the complex interactions between pro- and anti-inflammatory cytokines in AML may create a pro-tumorigenic microenvironment with effects on leukemic cell proliferation, survival and drug-resistance. This article summarizes current knowledge about the functions of pro- and anti-inflammatory cytokines in AML, their modes of action, and therapeutic interventions with potential to improve clinical outcomes for AML patients.
- Published
- 2018